相关实验视频

Updated: Sep 9, 2025

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding

Published on: September 15, 2010

特定亚型的HIV-1蛋白酶和杆和杆动态在药物耐药性中的作用:亚型C叙述

Dean Sherry¹, Zaahida Sheik Ismail¹, Tshele Mokhantso¹

¹Protein Structure-Function Research Laboratory, University of the Witwatersrand, Johannesburg 2000, South Africa.

|August 28, 2025

概括

由于HIV-1亚型的多样性和耐药性,HIV蛋白酶抑制剂 (PI) 面临着挑战. 本综述检查了HIV-1C亚型蛋白酶多态性,片灵活性和链动态,以启动新的治疗策略.

科学领域:

病毒学
药物发现
分子生物学

背景情况:

人类免疫缺陷病毒1型 (HIV-1) 酸蛋白酶是抗逆转录病毒治疗的关键点.
目前的艾滋病毒/艾滋病治疗依赖于蛋白酶抑制剂 (PI) 与其他抗逆转录病毒药物结合使用.
现有PI已被开发用于HIV-1亚型B,由于全球亚型多样性和新兴药物耐药性,这就带来了挑战.

研究的目的:

审查HIV-1亚型C蛋白酶基因变异对耐药性的影响.
分析这些多形态如何影响蛋白酶的灵活性和链区域的动态.
探索新的抑制策略,以解决目前针对各种HIV-1菌株的PI的局限性.

主要方法:

对HIV-1亚型C蛋白酶的现有文献的审查.
对遗传多态的分析及其与药物耐药性的相关性.
检查蛋白质酶的结构和动态特性,包括的灵活性和链区域的移动性.

主要成果:

艾滋病毒-1 亚型C蛋白酶表现出独特的多态性,有助于降低对现有的PIs的敏感性.
这些遗传变异影响蛋白酶的灵活性和链区域的动态,影响抑制剂的结合.
由于基因多样性和耐药性突变,目前的PI在有效向HIV-1亚型C方面存在局限性.

结论:

对于开发有效的抗逆转录病毒疗法,了解HIV-1C亚型蛋白酶多态性至关重要.
需要新的药物设计策略来克服耐药性并适应病毒遗传多样性.
未来的研究应集中在针对特定的HIV-1亚型,特别是C亚型的抑制剂上,以改善治疗结果.

关键词:

艾滋病毒-1 亚型 C 蛋白酶基因组分类型类抑制剂药物耐药性突变双作用抑制剂翻盖的灵活性遗传多样性链区域的动态类抑制剂蛋白酶抑制剂

更多相关视频

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...